Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
4.3 ANALYSIS OF TRADITIONAL AND NOVEL PRODUCTS
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMOLOGY
6.1 INCIDENCE RATE
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.14 CURRENT DEVELOPMENT SCENARIO
11 MARKET OVERVIEW
11.1 DRIVERS
11.2 RESTRAINS
11.3 OPPURTUNITY
11.4 CHALLENGES
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY TYPE
(NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS OF PRODUCT)
14.1 OVERVIEW
14.2 IGG
14.2.1 IGG1
14.2.2 IGG2
14.2.3 IGG3
14.2.4 IGG4
14.3 IGA
14.3.1 IGA1
14.3.2 IGA2
14.4 IGM
14.5 IGE
14.6 IGD
15 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY INDICATION
15.1 OVERVIEW
15.2 PRIMARY HUMORAL IMMUNODEFICIENCY DISEASE (PIDD)
15.2.1 COMMON VARIABLE IMMUNODEFICIENCY (CVID)
15.2.2 X-LINKED AGAMMAGLOBULINEMIA
15.2.3 CONGENITAL AGAMMAGLOBULINEMIA
15.2.4 WISKOTT-ALDRICH SYNDROME
15.2.5 SEVERE COMBINED IMMUNODEFICIENCIES (SCID)
15.3 IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
15.4 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
15.5 KAWASAKI’S VASCULITIS
15.6 MYASTHENIA GRAVIS
15.6.1 GENERALIZED MYASTHENIA GRAVIS
15.6.2 OCULAR MYASTHENIA GRAVIS
15.6.3 TRANSIENT NEONATAL MYASTHENIA GRAVIS
15.7 LUPUS
15.8 MYOSITIS
15.9 MULTIFOCAL MOTOR NEUROPATHY
15.1 GUILLAIN BARRÉ SYNDROME
15.11 HYPOPLASMINOGENEMIA
15.11.1 HEREDITARY
15.11.2 NONFAMILIAL
15.12 ACQUIRED IMMUNODIFICIENCY DISORDERS
15.13 CANCER
15.13.1 CHRONIC LYMPHOCYTIC LYMPHOMA
15.13.2 MULTIPLE MYELOMA
15.14 OTHER INDICATIONS
16 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY CONCENTRATION
16.1 OVERVIEW
16.2 IVIG 5%
16.3 IVIG 10%
17 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY AGE GROUP
17.1 OVERVIEW
17.2 PEDIATRIC
17.3 ADULT
17.4 GERIATRIC
18 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY DRUG TYPE
18.1 OVERVIEW
18.2 BRANDED DRUGS
18.2.1 GAMUNEX
18.2.2 FLEBOGAMMA DIF
18.2.3 GAMMAGARD S/D
18.2.4 GAMMAGARD LIQUID
18.2.5 GAMMAKED
18.2.6 GAMMAPLEX
18.2.7 GAMUNEX-C
18.2.8 OCTAGAM
18.2.9 PRIVIGEN
18.3 GENERIC
19 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS
19.3 SPECIALTY CLINIC
19.4 HOMECARE
19.5 OTHERS
20 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 HOSPITAL PHARMACY
20.3 RETAIL PHARMACY
20.4 OTHERS
21 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.2 COMPANY SHARE ANALYSIS: EUROPE
22.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.4 MERGERS & ACQUISITIONS
22.5 NEW PRODUCT DEVELOPMENT & APPROVALS
22.6 EXPANSIONS
22.7 REGULATORY CHANGES
22.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY GEOGRAPHY
GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.1.1. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, BY TYPE
23.1.1.2. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, BY INDICATION
23.1.1.3. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, BY CONCENTRATION
23.1.1.4. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, BY AGE GROUP
23.1.1.5. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, BY DRUG TYPE
23.1.1.6. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, BY END USER
23.1.1.7. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, BY DISTRUBUTION CHANNEL
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 FRANCE
23.2.3 U.K.
23.2.4 HUNGARY
23.2.5 LITHUANIA
23.2.6 AUSTRIA
23.2.7 IRELAND
23.2.8 NORWAY
23.2.9 POLAND
23.2.10 ITALY
23.2.11 SPAIN
23.2.12 RUSSIA
23.2.13 TURKEY
23.2.14 NETHERLANDS
23.2.15 SWITZERLAND
23.2.16 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 AUSTRALIA
23.3.6 SINGAPORE
23.3.7 THAILAND
23.3.8 MALAYSIA
23.3.9 INDONESIA
23.3.10 PHILIPPINES
23.3.11 VIETNAM
23.3.12 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 PERU
23.4.4 COLOMBIA
23.4.5 VENEZUELA
23.4.6 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 SAUDI ARABIA
23.5.3 UAE
23.5.4 EGYPT
23.5.5 KUWAIT
23.5.6 ISRAEL
23.5.7 REST OF MIDDLE EAST AND AFRICA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, COMPANY PROFILE
24.1 OCTAPHARMA AG
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 GRIFOLS
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 TAKEDA PHARMACEUTICALS U.S.A., INC.
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 ADMA BIOLOGICS.
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 BIOTEST UK.
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 CSL
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 KEDRION BIOPHARMA INC.
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 PROTHYA BIOSOLUTION
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 MERCK & CO., INC.
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 KAMADA PHARMACEUTICALS.
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 EMERGENT
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 LFB ( LABORATOIRE FRANÇAIS DU FRACTIONNEMENT DES BIOTECHNOLOGIES )
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 BIO PRODUCTS LABORATORY LTD.
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 JOHNSON AND JOHNSON
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 GC BIOPHARMA CORP.
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 NOVARTIS AG
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
24.18 BIOPHARMA PLASMA
24.18.1 COMPANY OVERVIEW
24.18.2 REVENUE ANALYSIS
24.18.3 GEOGRAPHIC PRESENCE
24.18.4 PRODUCT PORTFOLIO
24.18.5 RECENT DEVELOPMENTS
24.19 SYNERMORE BIOLOGICS
24.19.1 COMPANY OVERVIEW
24.19.2 REVENUE ANALYSIS
24.19.3 GEOGRAPHIC PRESENCE
24.19.4 PRODUCT PORTFOLIO
24.19.5 RECENT DEVELOPMENTS
24.2 RELIANCE LIFE SCIENCES
24.20.1 COMPANY OVERVIEW
24.20.2 REVENUE ANALYSIS
24.20.3 GEOGRAPHIC PRESENCE
24.20.4 PRODUCT PORTFOLIO
24.20.5 RECENT DEVELOPMENTS
24.21 TAJ PHARMA GROUP
24.21.1 COMPANY OVERVIEW
24.21.2 REVENUE ANALYSIS
24.21.3 GEOGRAPHIC PRESENCE
24.21.4 PRODUCT PORTFOLIO
24.21.5 RECENT DEVELOPMENTS
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
